The Mesoblast Ltd (ASX: MSB) share price could be in focus after the company secured US FDA approval for a new potency assay for its commercially approved Ryoncil (remestemcel-L-rknd). This milestone further strengthens quality controls for its flagship cell therapy product.
Image source: Getty Images
What did Mesoblast report?
- Received FDA approval for the T-cell Proliferation Inhibition BioAssay (TIBA), a new potency assay for Ryoncil.
- TIBA will be used alongside existing assays to ensure consistent product quality.
- Ryoncil remains the only FDA-approved MSC therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older.
- The new assay supports ongoing manufacturing improvements and quality monitoring for commercial product lots.
What else do investors need to know?
Mesoblast's updated testing process aims to improve the release and stability monitoring of each batch of Ryoncil. The TIBA assay offers added sensitivity to detect any changes in potency during manufacturing scale-up or when production shifts to new facilities.
Mesoblast continues to develop and expand its cell therapy portfolio, with Ryoncil being evaluated for additional diseases and rexlemestrocel-L in late-stage trials for heart failure and chronic lower back pain.
What's next for Mesoblast?
The new assay's FDA approval paves the way for smooth ongoing commercialisation of Ryoncil. Mesoblast remains focused on broadening Ryoncil's use to other inflammatory conditions and advancing its other cell therapies.
Investors can look for updates as the company works toward new product indications, international partnerships, and continued investment in manufacturing and intellectual property.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have declined 8%, trailing the S&P/ASX 200 Index (ASX: XJO), which is flat over the same period.
